Trial Profile

Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 27 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Jun 2025 Planned End Date changed from 1 Apr 2026 to 1 Jun 2026.
04 Jun 2024 Results (n=73; from 7/11/2019 to 4/13/2023) assessing the short course chemotherapy (FOLFOX + nivolumab (Nivo) followed by maintenance Nivo +/- radiation (RT)) and the potential of radiation in improving the efficacy of checkpoint inhibition in the first line treatment of metastatic or unresectable gastroesophageal adenocarcinoma, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
16 Jan 2024 Planned End Date changed from 1 Jan 2026 to 1 Apr 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com